BACKGROUND: Cryoballoon based catheter ablation (CB-CA) is an established therapy for treatment of symptomatic atrial fibrillation (AF). However, data about AF ablation using the CB in the diabetic population is sparse. The aim of this single center retrospective study is to evaluate the safety and efficacy of CB ablation in patients with diabetes mellitus (DM) as compared to patients without DM. METHODS AND RESULTS: Between July 2015 and December 2017, 397 consecutive patients underwent CB-CA for AF. Forty-eight consecutive patients with DM (DM group, study group) were compared with propensity score-matched patients without DM (n=48, control group). All patients underwent pulmonary vein isolation (PVI) using the second-generation CB (CB2). The mean age in the DM group was 66.9±9.5 years and 69.5±8.8 in the non-DM group (p=0.18). During a follow-up of 12.7±5.1 months, single procedure success rate for the DM and the non-DM group was 68.7% and 70.8%, respectively (p=0.82). The most common complication was transient phrenic nerve palsy (4 DM group vs. 0 non-DM group, p=0.04). No severe complication such as procedure related deaths, atrio-esophageal fistula or cerebrovascular embolic events occurred. CONCLUSIONS: Our data strengthen the value of CB2 based ablation for the treatment of AF as an effective and safe procedure in DM patients, with similar success rates when compared with a non-DM population.
BACKGROUND: Cryoballoon based catheter ablation (CB-CA) is an established therapy for treatment of symptomatic atrial fibrillation (AF). However, data about AF ablation using the CB in the diabetic population is sparse. The aim of this single center retrospective study is to evaluate the safety and efficacy of CB ablation in patients with diabetes mellitus (DM) as compared to patients without DM. METHODS AND RESULTS: Between July 2015 and December 2017, 397 consecutive patients underwent CB-CA for AF. Forty-eight consecutive patients with DM (DM group, study group) were compared with propensity score-matched patients without DM (n=48, control group). All patients underwent pulmonary vein isolation (PVI) using the second-generation CB (CB2). The mean age in the DM group was 66.9±9.5 years and 69.5±8.8 in the non-DM group (p=0.18). During a follow-up of 12.7±5.1 months, single procedure success rate for the DM and the non-DM group was 68.7% and 70.8%, respectively (p=0.82). The most common complication was transient phrenic nerve palsy (4 DM group vs. 0 non-DM group, p=0.04). No severe complication such as procedure related deaths, atrio-esophageal fistula or cerebrovascular embolic events occurred. CONCLUSIONS: Our data strengthen the value of CB2 based ablation for the treatment of AF as an effective and safe procedure in DM patients, with similar success rates when compared with a non-DM population.
Authors: Stefano Fumagalli; Salah A Said; Cecile Laroche; Debbie Gabbai; Serena Boni; Niccolò Marchionni; Giuseppe Boriani; Aldo P Maggioni; Agata Musialik-Lydka; Adam Sokal; Jens Petersen; Harry J G M Crijns; Gregory Y H Lip Journal: Eur Heart J Cardiovasc Pharmacother Date: 2018-07-01
Authors: Christian-Hendrik Heeger; Andreas Rillig; Dominic Geisler; Peter Wohlmuth; Thomas Fink; Shibu Mathew; Roland Richard Tilz; Bruno Reissmann; Christine Lemes; Tilman Maurer; Francesco Santoro; Osamu Inaba; Christian Sohns; YinHao Huang; Hannes Alessandrini; Inge Dotz; Michael Schlüter; Andreas Metzner; Karl-Heinz Kuck; Feifan Ouyang Journal: Circulation Date: 2019-01-29 Impact factor: 29.690
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld Journal: Europace Date: 2016-08-27 Impact factor: 5.214
Authors: Kivanc Yalin; Amr Abdin; Evgeny Lyan; Noureddin Sawan; Spyridon Liosis; Christian Elsner; Alexander Jobs; Ben Brüggemann; Jelena Koester; Ingo Eitel; Charlotte Eitel; Roland Richard Tilz Journal: Clin Res Cardiol Date: 2018-02-28 Impact factor: 5.460
Authors: Christian-Hendrik Heeger; Barbara Bellmann; Thomas Fink; Jan-Eric Bohnen; Erik Wissner; Peter Wohlmuth; Laura Rottner; Christian Sohns; Roland Richard Tilz; Shibu Mathew; Bruno Reissmann; Christine Lemeš; Tilman Maurer; Jakob Lüker; Arian Sultan; Tobias Plenge; Britta Goldmann; Feifan Ouyang; Karl-Heinz Kuck; Ilka Metzner; Andreas Metzner; Daniel Steven; Andreas Rillig Journal: Int J Cardiol Date: 2018-09-27 Impact factor: 4.164
Authors: Matteo Anselmino; Mario Matta; Fabrizio D'ascenzo; Carlo Pappone; Vincenzo Santinelli; T Jared Bunch; Thomas Neumann; Richard J Schilling; Ross J Hunter; Georg Noelker; Martin Fiala; Antonio Frontera; Glyn Thomas; Demosthenes Katritsis; Pierre Jais; Rukshen Weerasooriya; Jonathan M Kalman; Fiorenzo Gaita Journal: Europace Date: 2015-10 Impact factor: 5.214
Authors: Xin Du; Toshiharu Ninomiya; Bastiaan de Galan; Edward Abadir; John Chalmers; Avinesh Pillai; Mark Woodward; Mark Cooper; Stephen Harrap; Pavel Hamet; Neil Poulter; Gregory Y H Lip; Anushka Patel Journal: Eur Heart J Date: 2009-03-11 Impact factor: 29.983
Authors: Amr Abdin; Kivanc Yalin; Evgeny Lyan; Noureddin Sawan; Sypridon Liosis; Roza Meyer-Saraei; Christian Elsner; Stefan A Lange; Christian-Hendrik Heeger; Charlotte Eitel; Ingo Eitel; Roland Richard Tilz Journal: Clin Res Cardiol Date: 2018-09-05 Impact factor: 5.460